Yixiao Yu
Aikenwei Pharmaceutical Technology (Shanghai) Co., Ltd., Shanghai 200126, China.
*Corresponding author: Yixiao Yu
Abstract
Objective: To investigate the antibacterial activity and clinical efficacy of polymyxin B combined with carbapenem antibiotics against carbapenem resistant Klebsiella pneumoniae (CRKP), and analyze its medication safety. Methods: By reviewing relevant literature, the mechanism of action of polymyxin B combined with carbapenem antibiotics was analyzed, including complementary targets and synergistic cell membrane damage. At the same time, based on comprehensive clinical research reports, evaluate the impact of different drug combinations, infection sites, populations, and treatment courses on treatment efficacy, as well as safety risks such as nephrotoxicity and neurotoxicity. The primary target audience consists of patients infected with CRKP, involving different age groups, infection sites, and treatment plans. Results: The combination of polymyxin B and carbapenem antibiotics can enhance the antibacterial activity against CRKP through multiple mechanisms. However, clinical treatment efficacy is influenced by multiple factors, and there are safety risks involved. Conclusion: Therefore, when using combination therapy, it is necessary to develop a reasonable treatment plan based on the patient's condition, infection site, and drug characteristics, and closely monitor the safety of medication to ensure rational clinical use. This study provides new ideas for the treatment of CRKP infection, but further clinical research is needed to verify its effectiveness and safety.
References
[1] Chen J, Xia B, Liu Y, et al. Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: a retrospective cohort study. Ann Med. 2024;56(1):2397087.
[2] Lu J, Ma Y, Cao Z, et al. Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin. Microbiol Spectr. 2024:e0177024.
[3] Zhao Z, Yang T, Xiang G, et al. A novel small RNA PhaS contributes to polymyxin B-heteroresistance in carbapenem-resistant Klebsiella pneumoniae. Emerg Microbes Infect. 2024;13(1):2366354.
[4] Wang P, Liu S, Qi G, et al. Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant Klebsiella pneumoniae infection. Front Microbiol. 2023;14:1226981.
[5] Vieceli T, Rech RL, Henrique HT, et al. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. J Infect Chemother. 2024;30(7):621-5.
[6] Zhong C, Lin S, Li Z, et al. Characterization of carbapenem-resistant Klebsiella pneumoniae in bloodstream infections: antibiotic resistance, virulence, and treatment strategies. Front Cell Infect Microbiol. 2025;15:1541704.
[7] Thacharodi A, Vithlani A, Hassan S, et al. Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens. iScience. 2024;27(12):111367.
[8] Giuliano G, Sambo M, Castellani P, et al. Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports and review of the literature. Eur J Clin Microbiol In-fect Dis. 2024;44(1):1-4.
How to cite this paper
Clinical Study of Polymyxin B Combined with Carbapenem Antibiotics in the Treatment of Carbapenem-resistant Klebsiella Pneumoniae Infection
How to cite this paper: Yixiao Yu. (2025) Clinical Study of Polymyxin B Combined with Carbapenem Antibiotics in the Treatment of Carbapenem-resistant Klebsiella Pneumoniae Infection. International Journal of Clinical and Experimental Medicine Research, 9(3), 334-338.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.05.015